These companies aren't household names, but they quietly enable customers across the pharmaceutical and biopharmaceutical sectors to bring innovative new products to market.
News & Analysis: Repligen
Sometimes stocks go up, sometimes they go down.
The bioprocessing leader is having a bad day, but there doesn't appear to be any reason to panic.
The bioprocess engineering leader continued to deliver spectacular growth and bolster its profitability.
The under-the-radar biotech reported record quarterly revenue during the third quarter.